INS and type 2 diabetes mellitus: An oral long-acting acylated insulin analogue co-formulated with an absorption enhancer (I338) assessed in an 8-week trial in people with type 2 diabetes treated with oral glucose-lowering drugs, showed no difference in the magnitude of hypoglycemia or rates of adverse events detected in people randomized to I338 vs. insulin glargine [3].